A Prospective, Multicentre, Uncontrolled, Phase Ib/II Study of LY2780301 in Combination With Weekly Paclitaxel in HER2-negative Metastatic or Locally Advanced Breast Cancer in Patients With and Without PI3/AKT/S6 Pathway Activation. - TAKTIC-IPC 2012-008
Phase of Trial: Phase I/II
Latest Information Update: 09 Dec 2016
At a glance
- Drugs LY 2780301 (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TAKTIC
- 07 Jun 2017 Biomarkers information updated
- 08 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jul 2017.
- 30 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.